CD274 and neoplasm: Due to this, the administration of anti‐PD‐L1 antibodies further enhances the efficacy of radiotherapy through the cytotoxic T‐cell‐dependent mechanism.[7] But in fact, anti‐PD‐L1 monoclonal antibodies have some inevitable disadvantages, such as immunogenicity problems, poor tumor tissue permeability, relatively high cost, and limited efficacy.